Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials

Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials

Unlike other nonnucleoside reverse transcriptase inhibitors, etravirine is only approved for use in treatment-experienced patients. In the DUET 1 and 2 trials, 1203 highly treatment-experienced patients were randomized to etravirine or placebo, in combination with darunavir/ritonavir and optimized b...

Full description

Bibliographic Details
Main Authors:	Mark Nelson, Andrew Hill, Yvon van Delft, Christiane Moecklinghoff
Format:	Article
Language:	English
Published:	Hindawi Limited 2014-01-01
Series:	AIDS Research and Treatment
Online Access:	http://dx.doi.org/10.1155/2014/636584

Similar Items

Profile of etravirine in the treatment of HIV in pediatrics
by: Dehority W, et al.
Published: (2013-07-01)

Profile of etravirine for the treatment of HIV infection
by: Alice Tseng, et al.
Published: (2010-01-01)

Etravirine Pharmacokinetics In HIV-Infected Pregnant Women
by: Nikki Mulligan, et al.
Published: (2016-08-01)

The MONET trial: correlation between Hepatitis C coinfection and HIV RNA responses during darunavir/ritonavir monotherapy, for patients with HIV RNA <50 copies/mL at baseline
by: Prakash Manyu, et al.
Published: (2010-05-01)

No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trial.
by: Ajantha Solomon, et al.
Published: (2014-01-01)

The role of etravirine in the management of treatment-experienced pediatric patients with HIV
by: Osterholzer D
Published: (2013-04-01)

Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network
by: Kelly Gebo, et al.
Published: (2013-01-01)

Canadian Consensus Guidelines for the Optimal Use of Etravirine in the Treatment of HIV-Infected Adults
by: Marianne Harris, et al.
Published: (2009-01-01)

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients
by: Niccolò Riccardi MD, et al.
Published: (2019-01-01)

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
by: Thomas Kakuda, et al.
Published: (2012-01-01)

Allergic hypersensitivity to antiretroviral drugs: etravirine, raltegravir and darunavir
by: Manuel Anastacio Sánchez-Olivas, et al.
Published: (2015-04-01)

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection
by: Rosso R, et al.
Published: (2009-03-01)

Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV
by: Paula Munderi, et al.
Published: (2019-07-01)

Decreased phenotypic susceptibility to etravirine in patients with predicted genotypic sensitivity.
by: Eva Agneskog, et al.
Published: (2014-01-01)

Experimental data of co-crystals of Etravirine and L-tartaric acid
by: Mikal Rekdal, et al.
Published: (2018-02-01)

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial
by: Eduardo Arathoon, et al.
Published: (2017-01-01)

Pharmacoeconomic analysis of the etravirine compared to raltegravir in treatment HIV-infected adult patients, previously treated with antiretroviral drugs
by: Y. I. Ashikhmin, et al.
Published: (2018-05-01)

Clinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected population.
by: Luis F López-Cortés, et al.
Published: (2014-01-01)

Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
by: Charlotte Charpentier, et al.
Published: (2013-01-01)

Development of a practical synthesis of etravirine via a microwave-promoted amination
by: Da Feng, et al.
Published: (2018-12-01)

Efficacy and safety of darunavir and etravirine in a patient with retroviruses and multiple virologic failure
by: Claudia Bernardini, et al.
Published: (2009-09-01)

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
by: Ivanovic Jelena, et al.
Published: (2011-05-01)

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients
by: Catherine Orrell, et al.
Published: (2015-01-01)

Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens
by: Valérie Potard, et al.
Published: (2018-07-01)

Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study.
by: Patricia Echeverría, et al.
Published: (2014-01-01)

Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism.
by: Leïla Belkhir, et al.
Published: (2016-01-01)

Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1
by: Rolando M Viani
Published: (2010-06-01)

Cardiovascular side effects of the antiretroviral agents rilpivirine, efavirenz, etravirine and abacavir : possible underlying mechanisms
by: Bergin, Hild
Published: (2014)

New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom
by: Gazzard B, et al.
Published: (2012-07-01)

Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach
by: Purushothaman Indu, et al.
Published: (2020-12-01)

Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
by: Phairote Teeranaipong, et al.
Published: (2016-01-01)

Long-Term Administration of Abacavir and Etravirine Impairs Semen Quality and Alters Redox System and Bone Metabolism in Growing Male Wistar Rats
by: Agnieszka Matuszewska, et al.
Published: (2021-01-01)

Suppression of HIV-1 replication by microRNA effectors
by: Levy Yves, et al.
Published: (2009-03-01)

Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials.
by: Philippe Flandre
Published: (2011-01-01)

Bone outcomes in virally suppressed youth with HIV switching to tenofovir disoproxil fumarate
by: Kate Braithwaite, et al.
Published: (2021-08-01)

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
by: Anna Maria Geretti, et al.
Published: (2015-01-01)

HIV-1 nef suppression by virally encoded microRNA
by: Brisibe Ebiamadon, et al.
Published: (2004-12-01)

Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options
by: Inkeun Park, et al.
Published: (2020-07-01)

A re-examination of global suppression of RNA interference by HIV-1.
by: Viraj R Sanghvi, et al.
Published: (2011-01-01)

HIV RNA Suppression and Immune Restoration: Can We Do Better?
by: Marilia Rita Pinzone, et al.
Published: (2012-01-01)

Cannot write session to /tmp/vufind_sessions/sess_cmvhnbdhk6385i5gubbklglq4u